Metabolon Files Patent Infringement Lawsuit against Stemina
<0> LHAAdam Handelsman, [email protected]_IR_PR </0>
Metabolon, Inc., a diagnostics and services company offering the industry’s leading biochemical profiling technology, announced today that it has filed a patent infringement lawsuit against Stemina Biomarker Discovery, Inc. in the US District Court for the Western District of Wisconsin. The lawsuit seeks a ruling that Stemina’s services directly infringe on US Patent 7,550,258 and US Patent 7,910,301 which relate to global analysis of complex biological samples for the discovery of biomarkers and pathways associated with drug action, toxicity and disease. The lawsuit requests monetary damages as well as an order permanently enjoining Stemina from continued acts of infringement.
Metabolon, Inc. has advanced the field of metabolomics by pioneering and patenting the industry’s leading biochemical biomarker discovery and profiling platform. It has developed the technology to quickly identify and measure all of the biochemicals in a biological sample through its proprietary global processing method. Through the generation and interpretation of data, this method provides a precise understanding of disease etiology and drug action, and advances personalized medicine beyond what genomics and other approaches can promise. Metabolon’s expertise is being embraced by a wide range of pharmaceutical, biotechnology, food and agricultural companies. Metabolytics, its biomarker discovery and analysis business, has completed over 450 client studies and processed over 50,000 samples for customers in 2011 alone. Building on its expertise in biochemistry understanding, Metabolon is also developing proprietary diagnostic tests to determine and track disease progression. For more information about Metabolon, please visit or contact Todd Lynch at or 919-287-3368.